false 0001513818 0001513818 2022-09-22 2022-09-22


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): September 22, 2022
Aravive, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-36361
 
26-4106690
 
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
 
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, Texas 77098
(Address of principal executive offices)
 
(936) 355-1910
(Registrants telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common stock, par value $0.0001 per share
 
ARAV
 
Nasdaq Global Select Market
 
*Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
Item 5.07. Submission of Matters to a Vote of Security Holders.  
 
On September 22, 2022, Aravive, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders voted on three (3) proposals (the “Proposals”) and cast their votes as described below.  These Proposals are described in detail in the Company’s definitive proxy statement on Schedule 14A for the Annual Meeting, which was filed on August 4, 2022 with the Securities and Exchange Commission (the “Definitive Proxy Statement”).
 
The final results for the Proposals as set forth in the Definitive Proxy Statement are as follows:
 
Proposal 1Election of Directors
 
The following three (3) individuals were elected as Class II directors, each to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified, with the following votes:
 
Name of Director
 
Votes For
 
Withheld
 
Broker Non-Votes
             
1. Amato Giaccia, Ph.D.
  15,942,413   1,172,994   6,745,574
2. John Hohneker, M.D.
  16,023,996   1,091,411   6,745,574
3. Michael Rogers
  16,026,095   1,089,312   6,745,574
 
 
Proposal 2 Ratification of Appointment of Independent Registered Public Accounting Firm
 
The stockholders ratified and approved the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022, based on the votes set forth below:
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
             
23,253,136   550,853   56,992   0
 
 
Proposal 3Advisory vote on the approval executive compensation
 
The stockholders approved, on an advisory basis, the compensation of the Company’s named executed officers based on the votes set forth below:
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
             
16,552,403   535,003   28,000   6,745,574
 
 
Item 9.01.   Financial Statements and Exhibits.
 
(d) Exhibits.
     
Exhibit
Number
 
Description
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Date: September 22, 2022
ARAVIVE, INC.
(Registrant)
By:
/s/ Gail McIntyre
Name: Gail McIntyre
Title: Chief Executive Officer